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Abstract
There is a correlation between the severity of clinical symptoms and ventilation disorders in chronic 
obstructive pulmonary disease (COPD) patients and degree of blood coagulation system disorders. 
Patients with severe bronchial obstruction form the most challenging category in terms of disease 
prognosis. Some reports state that impaired haemostasis in COPD patients can be corrected with both 
anti-inflammatory agents and bronchodilators. However, the effects of medications commonly 
administered to treat COPD on haemostasis remain understudied. 
Aim: to evaluate the effects of adequate two-component standard treatment on platelet-vessel 
wall interaction and coagulation status of patients with severe COPD in view of severity of systemic 
inflammation. 
Materials and methods. We have examined 30 patients with severe COPD (FEV1<50% pred.) in a 
stable phase. Prior to inclusion in the study, patients did not receive any adequate therapy with inhaled 
glucocorticosteroids (IGCS) or long-acting bronchodilators, or a combination thereof. All patients were 
screened twice – at baseline and two months after assignment of adequate standard therapy. Patients’ 
complaints and disease history were carefully reviewed, objective data were collected, and functional and 
blood tests to assess hemorheology status and severity of systemic inflammatory were performed at 
baseline (Visit 1). COPD treatment was corrected for all patients during this visit: two-component 
therapy with salmeterol and fluticasone propionat in a fixed combination. After two months (Visit 2), in 
addition to re-evaluation of clinical symptoms, pulmonary ventilation function was measured, laboratory 
tests were performed and therapy compliance was assessed for all patients. 
Results. Since there no adequate standard treatment is available for COPD patients disorders develop in 
both platelet-vessel wall interaction and coagulation parts of haemostasis. Use of two-component 
standard treatment for two months helps stabilise the extrinsic pathway of the coagulation cascade, 
reduce platelet adhesion activity and decrease systemic inflammation, and has no effect on other 
parameters of the coagulation component of haemostasis. 
Conclusion. Adequate standard treatment of patients with severe COPD helps stabilise disorders of the 
coagulation part of haemostasis in the extrinsic coagulation pathway and causes no effects on the 
platelet-vessel wall interaction component of haemostasis. 
Keywords: chronic obstructive pulmonary disease, haemostasis, coagulation, platelet adhesion. 
Introduction 
It is currently known that patients with chronic obstructive pulmonary disease (COPD) 
respond to hypoxia by developing compensatory stimulation of erythropoiesis, hypercapnia, 
hypokalemia or respiratory acidosis [6, 11, 14]. These disorders can increase the activity of 
coagulation factors [18, 19]. On the other hand, data show that increased production of 
proinflammatory cytokines in COPD patients can cause the destruction of the endothelial 
tissue of blood vessels. It also contributes to abnormal hemorheology status [15, 17, 18, 19] of both 
platelet-vessel wall interaction [7, 13] and coagulation [3, 12] components. 
Clinical study results demonstrate that there is a close correlation between the severity of 
clinical symptoms/ventilation disorders in COPD patients and degree of blood coagulation 
system disorders [3, 12, 16, 17]. It means that COPD patients, especially those with severely 
impaired pulmonary ventilation function (PVF) and a number of symptoms, need special care 
from clinicians so that risks of haemostasis disorders can be identified and for timely 
preventive therapy [8, 16]. 
There are recent data in scientific literature indicating that abnormal haemostasis in COPD 
patients can be corrected with both anti-inflammatory agents [1, 3, 4] and bronchodilators [5].  
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Commonly administered by such patients. V. K. Havrysyuk et 
al. [1] showed that platelet aggregation activity significantly 
reduced after just one day of fenspiride hydrochloride dosing 
in COPD patients, while the studies conducted by 
D. V. Dobryanskyi [3] demonstrated that three-week treatment 
with fenspiride hydrochloride also had a positive effect on 
rheological properties of blood. M. M. Yehorova [5] suggests 
that use of tiotropium bromide in COPD patients causes 
bronchodilation and can also enhance coagulation properties of 
blood improving overall hemorheology profile. 
However, the mechanisms of disorders of the platelet-vessel 
wall interaction and coagulation elements of haemostasis in 
COPD patients as well as the levels at which those disorders 
occur still remain understudied and effects of medications 
commonly administered to treat bronchial obstruction are 
poorly explored. 
In view of the aforesaid and taking into account that patients 
with severe bronchial obstruction form the most challenging 
category in terms of disease prognosis, the aim of our study 
was to evaluate the effects of two-component adequate 
standard treatment (Seretide® Discus® combination therapy) 
on platelet-vessel wall interaction and coagulation status of 
patients with severe COPD in view of severity of systemic 
inflammation. 
 
Materials and methods 
We have examined 30 patients with severe COPD (all patients 
had stage III or IV disease and were classified as category C 
and category D patients) in a stable pathological process phase 
(25 (83. 3%) men and 5 (16, 7%) women; mean age was 
65.4±7.9 years) who formed the main group. All patients had a 
history of active smoking or were active smokers at screening 
(with a pack/year factor 38.1±14.7). Prior to inclusion in the 
study, patients did not receive any adequate therapy with 
inhaled glucocorticosteroids (IGCS) or long-acting 
bronchodilators, or a combination thereof (or did not take 
those medications, or were not taking them on a regular basis, 
or were taking them in inadequate doses). During at last two 
last months, patients were receiving a combination drug 
containing short-acting bronchodilators (fenoterol, a short-
acting β2-agonist, and ipratropium bromide, a short-acting anti-
cholinergic drug) in 4 to 8 inhalation doses daily, and, where 
necessary, salbutamol (200 g dose). 
All patients gave their written informed consent to participate 
in the study. 
COPD was diagnosed pursuant to Order No.555 of the 
Ministry of Health of Ukraine dated June 27, 2013 [9]. Patients 
a history of and current severe cardiovascular disorders at 
screening, a history of severe heart failure, thromboembolism 
associated with venous insufficiency of the lower extremities, 
a history of and current cancer at screening, or obesity were 
excluded from the study. 
All patients were screened twice – at baseline and two months 
after assignment of adequate standard therapy. 
Patients’ complaints and disease history were carefully 
reviewed, objective data were collected, and functional and 
laboratory tests were performed at baseline (Visit 1). COPD 
treatment was corrected for all patients during this visit: two-
component therapy with a long-acting β2-agonist (salmeterol) 
and an inhaled corticosteroid (IGCS) (fluticasone propionat) in 
a fixed combination (Seretide® Discus® 50/500 g, 1 
inhalation dose BID) and, where necessary, salbutamol 
(200 g dose). All patients were also instructed about the need 
to take adequate therapy, received recommendations for daily 
monitoring of clinical symptoms, and all possible side effects 
of the drug components were explained. 
After two months (Visit 2), in addition to re-evaluation of 
clinical symptoms, PVF was measured, blood tests to assess 
hemorheology status were performed and therapy compliance 
was assessed for all patients. Therapy compliance was 
measured by the number of Seretide® Discus® doses taken 
over two months as percentage of the drug amount which was 
supposed to be administered over that period. Compliance was 
considered sufficient if the value was between 80% and 120%, 
and insufficient if the value was beyond those limits. 
The control group for haemostasis assessment included 
19 virtually healthy individuals comparable with COPD 
patients by age and sex (mean age was 54.4±3.4 years; 15 men 
(78.9%) and 4 women (21.1%)). Participants in the examined 
control group also had a history of active smoking or were 
active smokers at screening (with a pack/year factor 
35.2±13.8). 
Cough expression and sputum quantity were measured by 
using V. M. Savchenko’s method [10], cough severity — with a 
5-point scale (where 0 means no cough; 1 — rare, insignificant 
cough; 2 — frequent but not activity-limiting cough; 3 — 
frequent, activity-limiting cough; 4 — cough that attracts 
attention for most part of the day); sputum quantity — with a 
5-point scale (where 0 means no sputum; 1 — insignificant 
amount; 2 — moderate amount; 3 — much; 4 — very much). 
To assess dyspnoea severity we used the modified British 
Medical Research Council (mMRC) scale recommended for 
COPD patients and containing 5 grades of dyspnoea. 
The global effects of the disease on patient’s daily life were 
measured with the 8-items COPD Assessment Test (CAT) 
with possible total score from 0 to 40. [9]. 
PVF was assessed with a morning fasting computer-based 
spirometry study by using Master Screen Body/Diff system 
(Jager, Germany). Levels of forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) as percentage 
of the predicted value as well as the FEV1/FVC ratio were 
calculated. Reversibility of bronchial obstruction was 
measured by the change in FEV1 absolute value (mL) after 
inhalation of 400 g of a short-acting β2-agonist (salbutamol). 
To assess the status of the extrinsic coagulation pathway of 
haemostasis we used prothrombin index (PI) which, if 
increased, indicates disorders of coagulation properties of the 
blood towards hypercoagulability; prothrombin ratio (PR) and 
international normalised ratio (INR), one of the key parameters 
of the state of the coagulation system and a standard factor of 
coagulation efficiency of the blood clotting system. 
For the intrinsic and common pathways of the coagulation 
cascade we assessed the activated partial Thromboplastin time 
(aPTT), a versatile measure of deficit of all coagulation 
factors. 
To assess procoagulant activity in haemostasis we measured 
thrombin time (PT), a reduced value of which is a marker of 
abnormal fibrinogen to fibrin transformation and increased 
tendency to hypercoagulability, and fibrinogen (Fg) levels 
(g/L), the only factor of the coagulation system and an acute-
phase protein of inflammation. 
Anticoagulation system was assessed by measuring the levels 
of antithrombin III (AT III), the most important cofactor of 
anticoagulation mechanisms. 
The platelet-vessel wall interaction component of haemostasis 
was assessed by calculating the modified platelet adhesiveness 
(retention) index (PAI) (with glass beads). PAI was calculated 
by using the following equation: adhesiveness index (%) = 
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(number of pre-column platelets in blood – number of post-
column platelets in blood)/(number of pre-column platelets in 
blood) x 100%. Elevated PAI indicates the presence of 
haemostasis disorders in the platelet-vessel wall interaction 
component towards hypercoagulability. 
Plasma C-reactive protein (CRP) (mg/L) was measured as a 
systemic inflammation marker by immunoturbidimetric 
technique [17]. 
Statistical analysis of the results was performed by using 
biometric methods of analysis implemented in EXCEL-2003 
and STATISTICA 6.0 software packages [8, 12]. Significance of 
differences in mean values for unrelated samples was 
evaluated by using the Student’s t-test and Mann-Whitney U 
test, for related samples by the Wilcoxon signed-rank test and 
Student’s t-test for dependent groups. The difference between 
comparable values was considered reliable at p<0.05. 
 
Results and discussion 
During Visit 1, all patients were screened according to the plan 
and clinical diagnosis of severe COPD was verified for all 
patients. The results were processed for statistics purposes. 
However, though all patients were instructed at Visit 1 about 
the need for using adequate COPD therapy, at Visit 2 it was 
found out that approximately half (14 (46.7%)) of patients had 
poor therapy compliance: 10 (71.4%) of them for economic 
reasons (could not buy the drugs) and 4 (28.6%) due to 
personal fear of taking glucocorticoids. Laboratory tests were 
not performed for those patients at Visit 2. Patients who 
demonstrated sufficient therapy compliance (16 (53.3%), 12 
(75.0%) men and 4 (25.0%) women; mean age was 68.1±6.4 
years; pack/year factor was 32.6±17.1) formed subgroup 1 of 
the main group and had a full examination at Visit 2. 
Comparative statistical analysis was performed for the overall 
values of subgroup 1 of the main group measured at Visit 1, 
and for the values of subgroup 1 obtained at Visit 1 and 
Visit 2. The clinical parameters of patients in the main group 
and subgroup 1 did not show any significant difference (Table 
1). It means that subgroup 1 was representative by its clinical 
parameters. 
The analysis showed that at the time of Visit 1 all patients in 
subgroup 1, just as patients in the main group, had a great 
number of symptoms (>10 points by the CAT test). Two 
months later (Visit 2), improvement in daily activities and 
general health, as measured by the CAT test, and in individual 
clinical signs of the disease compared to baseline were seen in 
association with adequate administration of Seretide® 
Discus®. The clinical parameter levels in Table 1 are 
represented for convenience as the arithmetic mean (M) and 
error of mean (m). 
 
Table 1: Clinical Parameter Levels in COPD Patients by Treatment Stages 
 
Study Group 
Values (M±m) 
CAT (score) mMRC (score) cough (score) sputum (score) 
Main group (n=30): 
Subgroup 1 (n=16): 
at Visit 1 
at Visit 2 
16.50±1.16 
 
16.81±1.77 
14.56±1.52 
2.17±0.15 
 
2.31±0.24 
1.63±0.13 
1.23±0.11 
 
1.19±0.16 
0.81±0.10 
1.40±0.14 
 
1.38±0.22 
0.50±0.13 
p 
рm-р1>0.05 
р1-р2<0.05 
pm-р1>0.05 
р1-р2<0.05 
рm-р1>0.05 
р1-р2<0.05 
рm-р1>0.05 
р1-р2<0.05 
Note: 
1. m— main group; 
2. 1— subgroup 1 at Visit 1; 
3. 2— subgroup 1 at Visit 2. 
 
PVF levels in patients of the main group and subgroup 1 did 
not show any significant difference (Table 2). This means that 
subgroup 1 was representative by PVF levels. 
FEV1 and FVC levels in patients from subgroup 1 at Visit 2 
did not differ significantly from those levels at Visit 1 
(p>0.05), though an increase in the FEV1/FVC ratio compared 
to baseline was noted (p<0.05). 
 
Table 2: PVF Levels in COPD Patients by Treatment Stages 
 
Study Group 
Parameters (Med [25–75%]) 
FEV1 
(% pred.) 
FVC 
(% pred.) 
FEV1/FVC 
Main group 
(n=30): 
Subgroup 1 
(n=16): 
at Visit 1 
at Visit 2 
44.2 [33.5–
46.1] 
 
39.9 [31.6–
45.1] 
42.0 [35.7–
46.4] 
84.1 [75.6–
88.5] 
 
88.1 [75.3–
95.7] 
87.5 [82.3–
92.2] 
0.38 [0.33–
0.49] 
 
0.35 [0.32–
0.39] 
0.38 [0.34–
0.46] 
p 
рm-р1>0.05 
р1-р2>0.05 
рm-р1>0.05 
р1-р2>0.05 
рm-р1>0.05 
р1-р2<0.05 
Note: please see Table 1. 
The analysis showed that the levels of the platelet-vessel wall 
interaction and coagulation elements of haemostasis in patients 
from the main group and subgroup 1 did not have any 
significant difference. Therefore, subgroup 1 was 
representative by the key haemostasis parameters. 
Prothrombin complex (PI, PR, INR) levels in patients of the 
main group at Visit 1, just as in patients from subgroup 1, were 
significantly different from those levels in the control group 
and were indicative of disorders in the coagulation component 
of haemostasis towards hypercoagulability (Table 3). 
Though the analysis of the coagulation element of haemostasis 
in patients from subgroup 1 showed that PI, PR and INR levels 
at Visit 2 and 2 months after therapy correction were different 
from those in the control group with a tendency towards 
hypercoagulability, it was determined that during Seretide® 
Discus® treatment PI level decreased significantly while PR 
and INR levels increased compared to baseline. These changes 
suggest that there is a positive effect of the two-component 
therapy on the extrinsic coagulation pathway parameters. 
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Table 3: Extrinsic Coagulation Pathway Parameters in COPD Patients 
 
Study Group Parameters (Med [25–75%]) PI (%) PR INR 
Main group (n=30): 
Subgroup 1 (n=16): 
at Visit 1 
at Visit 2 
109.0 [108.0–112.0] 
 
111.5 [109.0–117.0] 
103.0 [100.5–112.5] 
0.92 [0.89–0.93] 
 
0.89 [0.85–45.1] 
0.97 [0.89–0.99] 
0.90 [0.86–0.91] 
 
0.87 [0.82–0.90] 
0.96 [0.87–0.99] 
Control group (n=19) 97.0 [23.4– 28.2] 1.03 [1.0–1.05] 1.04 [1.0–1.06] 
p 
рm-рc<0.05 
рm-р1>0.05 
р1-рc<0.05 
р2-рc<0.05 
р1-р2<0.05 
рm-рc<0.05 
рm-р1>0.05 
р1-рc<0.05 
р2-рc<0.05 
р1-р2<0.05 
рm-рc<0.05 
рm-р1>0.05 
р1-рc<0.05 
р2-рc<0.05 
р1-р2<0.05 
Note: 
1. 1 — subgroup 1 at Visit 1; 
2. 2 — subgroup 1 at Visit 2; 
3. m — main group; 
4. c — control group. 
 
aPTT levels in both the main group of patients at visit 1 and 
subgroup 1 were significantly lower than those identified in 
control group (p<0.05) (Table 4). aPTT levels in subgroup 1 
after two months of treatment with Seretide® Discus® did not 
significantly change compared to baseline (p>0.05) and was 
significantly lower in the control group (p<0.05) which is 
indicative of abnormal coagulation haemostasis towards 
hypercoagulability and lack of effects of the two-component 
therapy on those disorders. 
As regards the procoagulant activity of haemostasis, PT and 
Fg levels in patients of the main group and subgroup 1 at 
Visit 1 were not significantly different from those in the 
control group. Following the correction therapy (at Visit 2), 
PT and Fg levels in subgroup 1 were identical to Visit 1 levels 
and did not show any significant difference with the control 
group. The assigned therapy had no significant effect on the 
two last parameters. No changes in PT, that characterises the 
common pathway of the coagulation cascade, and changes in 
aPTT levels towards hypercoagulability all show that there are 
haemostasis disorders mainly in the intrinsic pathway of the 
coagulation cascade in patients with severe COPD. 
 
Table 4: Parameters of Intrinsic and Common Pathways of 
Coagulation Cascade in COPD Patients 
 
0 
Parameters (Med [25–75%]) 
aPTT (s) PT (s) Fg (g/L) 
Main group 
(n=30): 
Subgroup 1 
(n=16): 
at Visit 1 
at Visit 2 
22.2 [18.2–
24.0] 
 
22.5 [18.6–
23.8] 
22.2 [21.0–
23.4] 
16.3 [15.3–
16.8] 
 
16.0 [15.3–
16.7] 
15.5 [15.8–
17.2] 
3.5 [3.1–
4.0] 
 
3.5 [3.2–
3.9] 
3.5 [2.7–
4.4] 
Control group 
(n=19) 
26.4 [23.4– 
28.2] 
16.5 [15.7–
17.6] 
3.1 [2.6–
3.5] 
p 
рm-рc<0.05 
рm-р1>0.05 
р1-рc<0.05 
р2-рc<0.05 
р1-р2>0.05 
pm-рc >0.05 
рm-р1>0.05 
р1-рc >0.05 
р2-рc >0.05 
р1-р2>0.05 
pm-рc >0.05 
рm-р1>0.05 
р1-рc >0.05 
р2-рc >0.05 
р1-р2>0.05 
Note: please see Table 3. 
 
It should be noted that AT III levels in patients of the main 
group (96.0 [82.0-107.0]%) were not significantly different 
from those in the control group. In subgroup 1, this value both 
before and after therapy correction (Visit 2) (87.5 [77.5–103.5] 
and 88.0 [84.0–101.0]%, respectively) was lower than in the 
control group (103.0 [98.0–106.0]%), which means that 
examined patients have an increased tendency to 
hypercoagulability. Therefore, a two-month course of 
Seretide® Discus® treatment had an insignificant effect on 
this value. These changes are indicative of both zero response 
from the anticoagulation blood system to coagulation disorders 
in COPD patients of the main group and inhibition of the 
fibrinolytic blood system in patients of subgroup 1, which was 
reported in the literature [2, 8]. 
The change in the coagulation component of haemostasis 
means that COPD patients are predisposed to 
hypercoagulability. Unless the disease is adequately treated, 
abnormalities develop in both the extrinsic and intrinsic 
coagulation pathways. However, even a two-month course of a 
two-component therapy with Seretide® Discus® contributes to 
stabilisation of haemostasis disorders in such patients to some 
extent. 
As for the platelet-vessel wall interaction component of 
haemostasis, the PAI levels in patients of the main group at 
Visit 1, just as in patients of subgroup 1 (45.5 [37.0–53.0] and 
37.0 [33.5–43.5]%, respectively) were significantly higher 
than in the control group (27.0 [22.0–33.0]%) (p<0.05). After 
two months of Seretide® Discus® treatment, the levels in 
subgroup 1 (35.0 [27.0–44.0]%) decreased significantly 
compared to baseline (p<0.05) and was identical to the value 
obtained for the control group (p<0.05). Such PAI levels mean 
that the two-component treatment had a positive effect on the 
adhesive activity of platelets. 
CRP levels at Visit 1 in both patients of the main group and 
subgroup 1 (5.59 [5.1–7.4] and 6.1 [5.7–9.7] mg/L, 
respectively) were significantly higher than in the control 
group (3.2 [3.6–3.8] mg/L) (p<0.05), which demonstrates the 
severity of the systemic inflammatory response in COPD 
patients. CRP levels in patients of the main group and 
subgroup 1 did not show any significant difference. Therefore, 
subgroup 1 was representative by this value. 
Though CRP in patients of subgroup 1 both at Visit 2 
(5.2 [4.7–6.8] mg/L), respectively) was significantly higher 
than in the control group (p<0.05), after two months of 
treatment with Seretide® Discus® the levels decreased 
significantly compared to baseline (p<0.05) and approximated 
the levels of the control group, please see Fig. 1. 
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Fig. 1: CRP levels in patients with severe COPD by treatment stages. 
 
Our data indicate that an adequate two-component standard 
treatment of patients with severe COPD may decrease the 
severity of systemic inflammatory response and, therefore, 
may help normalise the coagulation element of haemostasis. A 
search for new methods to correct of haemostasis in COPD 
patients, especially in those with severe and distinct clinical 
symptoms, is a promising area of the future research. 
 
Conclusions 
1. Haemostasis disorders develop in both platelet-vessel 
wall interaction and coagulation parts of haemostasis of 
severe COPD patients since there no adequate standard 
treatment is available for them. 
2. An adequate standard treatment of patients with severe 
COPD helps stabilise disorders of the coagulation part of 
their haemostasis in the extrinsic coagulation pathway. 
3. An adequate standard treatment of patients with severe 
COPD has a positive effect on platelet adhesion activity 
and helps stabilise the platelet-vessel wall interaction 
component of haemostasis. 
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